DSGN: Design Therapeutics Narxning sof foyda o‘sishiga nisbati
Design Therapeutics Fuchs distrofiyasi va ataksiyaga qarshi kurashish uchun inqilobiy GeneTACs texnologiyasini joriy etmoqda va patent ustunligiga intilmoqda. GURU.Markets platformasida PEG adolatli qiymati dinamikasini tahlil qilish orqali biz 0.00 qiymati metrika darajasini ifodalashini kuzatmoqdamiz. Bozor kapitalizatsiyasi irsiy patologiyalar uchun gen terapiyalarini ishlab chiqishga asoslangan, ekologik siyosat esa qat'iy biosafety nazorati va chiqindilarni utilizatsiya qilishga tayanadi.
Design Therapeutics (DSGN) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- balans kapitallashuvi bo'yicha ma'lumotlar:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Jamlagan qarzning kapitalga nisbati Design Therapeutics|DSGN - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati designtx.com|DSGN - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Design Pharma|DSGN - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli kredit va qarzlari Design Therapeutics|Tezkor likvidlik koeffitsiyenti designtx.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
DSGN - Kompaniyaning sof foydasi|Forvard foyda Design Therapeutics|DSGN - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Design Corp|DSGN - Narx-foyda va o‘sish multiplikatori|EV/EBITDA multiplikatori Design Pharma|DSGN - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun foyda Design Therapeutics|DSGN - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi designtx.com|DSGN - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Design Therapeutics
Kompaniyaning umumiy tahlili:DSGN - Design Therapeutics Inc
Design Therapeutics (DSGN) tadqiqotlaridagi murakkab biosample logistikasi biznesning o'sish sur'atlariga bevosita ta'sir ko'rsatadi, bu esa PEG koeffitsiyenti tarixida aks etgan. Ushbu ko'rsatkich P/E multiplikatorini kutilayotgan foyda o'sish sur'atiga bo'ladi va qiymat birdan past bo'lganda, ya'ni kengayish potentsiali aksiyalarning joriy bozor qiymatidan ustun kelganida, qadrsizlangan aktivlarni aniqlash imkonini beradi.
Design Therapeutics raqobatchilari
O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Tempus AI, Inc|PEG multiplikatori QGEN (Qiagen Group)|Narxning sof foyda o‘sishiga nisbati Isis Pharmaceuticals|RGEN - Narxning foydaga va o‘sish sur’atiga nisbati|RNA (aviditybiosciences.com) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|CRSP (CRISPR Therapeutics) - Narx-foyda va o‘sish multiplikatori|GeneDx Holdings - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narx-foyda va o‘sish multiplikatori RARE|BEAM (Beam Tx) - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|PEG multiplikatori SRPT|TWST (twistbioscience.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori TXG (10x Genomics)|Intellia Therapeutics Inc (NTLA) - O‘sish sur’atiga tuzatilgan narx-foyda|STOK - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti BLFS (BioLife)|WVE: PEG multiplikatori|mazetx.com (MAZE) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati Sionna Therapeutics|Prime Medicine Inc - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori TSHA|QURE - O‘sish sur’atiga tuzatilgan narx-foyda|MeiraGTx Holdings plc - Narx-foyda va o‘sish multiplikatori|PEG multiplikatori regenxbio.com RGNX|SLDB: Narx-foyda va o‘sish multiplikatori|Ocugen Inc - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|PACB: PEG multiplikatori|BNTC - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|RCKT (Rocket Pharmaceuticals) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori 4dmoleculartherapeutics.com (FDMT)|Narxning foydaga va o‘sish sur’atiga nisbati Lexeo Therapeutics (LXEO)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati korrobio.com|PEG multiplikatori EDIT (Editas)|SLN: O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PRQR - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Codexis, Inc. CDXS|SGMO: PEG multiplikatori|Narxning sof foyda o‘sishiga nisbati Nautilus Bio NAUT|Narxning foydaga va o‘sish sur’atiga nisbati Metagenomi, Inc|O‘sishni hisobga olgan narx-foyda koeffitsiyenti DTIL (Precision BioSciences Inc.)|PEG multiplikatori GBIO|boundlessbio.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Exicure XCUR|IMNN: O‘sishni hisobga olgan narx-foyda koeffitsiyenti|RXi Pharmaceuticals - PEG multiplikatori|MBIO - PEG multiplikatori|RNAZ: PEG multiplikatori|O‘sishni hisobga olgan narx-foyda koeffitsiyenti BNGO|APDN (Applied DNA Sciences, Inc.) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda bluebird bio Inc. BLUE|Narxning foydaga va o‘sish sur’atiga nisbati ImmunoPrecise Antibodies (IPA)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Omega Therapeutics Corp|PEG multiplikatori OMIC (Singular Genomics Systems)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati regulusrx.com (RGLS)|Syros Pharmaceuticals, Inc. - PEG multiplikatori|Narxning sof foyda o‘sishiga nisbati Telesis Bio Inc. (TBIO)|TRACON (TCON) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sishni hisobga olgan narx-foyda koeffitsiyenti UBX
